Post-vaccination SARS-CoV-2 infection: risk factors and illness profile in a prospective, observational community-based case-control study

Michela Antonelli, PhD 1, Rose S Penfold, BMBCh 2,3, Jordi Merino, PhD 4,5,6, Carole H Sudre, PhD 1,7,8, Erika Molteni, PhD 1, Sarah Berry, PhD 2, Liane S Canas, PhD 1, Mark S Graham, PhD 1, Kerstin Klaser, MSc 1, Marc Modat, PhD 1, Benjamin Murray, MSc 1, Marc F Österdahl, MBBS 2,3, Nathan J Cheetham, PhD 2, David Drew, PhD 6, Long Nguyen, PhD 6, Joan Capdeila Pujol, PhD, 9, Christina Hu, MA 9, Somesh Selvachandran, MSc 9, Lorenzo Polidori, MS 9, Anna May, MSc 9, Jonathan Wolf, MA 9, Prof Andrew T Chan, MD, MPH 10, Prof Alexander Hammers, PhD 1,11, Prof Emma Duncan PhD 2, Prof Tim D Spector, PhD 2, Prof Sebastien Ourselin*, PhD 1, Claire J Steves*, PhD 2,3

1. School of Biomedical Engineering & Imaging Sciences, King's College London, London, UK
2. Department of Twin Research and Genetic Epidemiology, King's College London, UK
3. Department of Ageing and Health, Guys and St Thomas' NHS Foundation Trust, London, UK
4. Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
5. Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
6. Department of Medicine, Harvard Medical School, Boston, MA, USA
7. MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK
8. Centre for Medical Image Computing, University College London, London, UK
9. Zoe Global, London, UK
10. Clinical and Translational Epidemiology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
11. King's College London & Guy's and St Thomas' PET Centre

*These authors contributed equally.

Corresponding author: Claire J Steves, Department of Twin Research and Genetic Epidemiology, King's College London, St Thomas' Campus, Lambeth Palace Road SE1 7EH, claire.j.steves@kcl.ac.uk

Research in context

Evidence before this study:

To identify existing evidence for COVID-19 infection post-vaccination, we searched PubMed for peer-reviewed articles published between December 1, 2020 and May 18, 2021 using keywords ("COVID-19" OR "SARS-CoV-2") AND ("Vaccine" OR "vaccination") AND ("infection") AND ("risk factor*" OR "characteristic*"). We did not restrict our search by language or type of publication. Of 202 articles identified, we found no original studies on individual risk and protective factors for COVID-19 infection following vaccination nor on nature and duration of symptoms in vaccinated, community-based individuals. Social and occupational factors influence risk of COVID-19 exposure and infection and personal factors (age, male sex, multiple morbidities and frailty) increased risk for adverse outcomes in COVID-19 in unvaccinated populations. Phase III clinical trials have demonstrated good efficacy of BNT162b2 and ChAdOx1 vaccines against SARS-CoV-2 infection, confirmed in real-world data, which additionally showed reduced risk of adverse outcomes including hospitalisation and death.

Added value of this study:

This is the first observational study investigating characteristics of and factors associated with SARS-CoV-2 infection after COVID-19 vaccination. We found that vaccinated individuals with frailty had higher rates of infection after vaccination than those without. Adverse determinants of health (e.g. increased social deprivation, obesity or unhealthy lifestyle factors such as less healthy diet) were associated with higher likelihood of infection after vaccination. In comparison with unvaccinated individuals, individuals infected after vaccination had fewer symptoms of COVID-19, and more people were entirely asymptomatic. Fewer vaccinated individuals experienced five or more symptoms, required hospitalisation, and, in the older adult group, fewer had prolonged illness duration (symptoms lasting longer than 28 days).

Implications of all the available evidence:

Some individuals still contract COVID-19 after vaccination and our data suggest that frail older adults and those living in more deprived areas are more at risk. However, in most individuals illness appears less severe, with reduced need for hospitalisation and less risk of prolonged illness

duration. Our results are relevant for health policy post-vaccination and highlight the need to prioritise those most at risk, whilst also emphasising the balance between the importance of ongoing personal protective measures versus adverse effects from ongoing social restrictions. Strategies such as timely prioritisation of booster vaccination and optimised infection control could be considered for at-risk groups. Research is also needed on how to enhance the immune response to vaccination in those at higher risk.

Abstract

Background:

Both BNT162b2 and ChAdOx1 vaccines show good efficacy in clinical trials and real-world data. However, some still contract SARS-CoV-2 post-vaccination. This study identifies risk factors associated with SARS-CoV-2 infection at least 14 days after first vaccination and describes characteristics of post-vaccination illness.

Methods:

Cases were UK adults reporting post-vaccination SARS-CoV-2 infection between 8th December 2020 and 1st May 2021, reporting on the COVID Symptom Study app. We assessed the associations of age, frailty, comorbidity, area-level deprivation and lifestyle factors with infection (vaccinated cases vs. negative-vaccinated controls); and vaccination with illness profile (vaccinated cases vs positive-unvaccinated controls).

Findings:

Post-vaccination infection risk was substantially higher in older adults with frailty (OR= 2.78, 95% CI [1.98-3.89], p-value<0.0001) and in individuals living in most deprived areas (OR vs. intermediate group=1.22, 95%CI [1.04-1.43], p-value=0.01). Risk was lower in individuals with a healthier diet (OR=0.73, 95%CI [0.62-0.86], p-value<0.0001) and without obesity (OR=0.6, 95% CI [0.44-0.82], p-value=0.001). Vaccination was associated with reduced odds of hospitalisation (OR=0.36, 95%CI [0.28-0.46], p-value<0.0001), and high acute-symptom burden (OR=0.51, 95%CI [0.42-0.61], p-value<0.0001). In the 60+ age group, risk of >28 days illness was lower following vaccination (OR=0.72 , 95%CI [0.51-1.00], p-value=0.05). Most symptoms were reported less in positive-vaccinated vs. positive-unvaccinated individuals, except sneezing, which was more common post-vaccination (OR=1.24, 95%CI [1.05-1.46], p-value=0.01).

Interpretation:

Our findings highlight reduced symptom burden and duration in those infected post-vaccination. Whilst reassuring, our data should prompt efforts to boost vaccine effectiveness in at-risk

populations; moreover, targeted infection control measures will still be appropriate to minimise SARS-CoV-2 infection.

Funding:

This work is supported by UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre (BRC) award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust and via a grant to ZOE Global; the Wellcome Engineering and Physical Sciences Research Council (EPSRC) Centre for Medical Engineering at King's College London (WT 203148/Z/16/Z). Investigators also received support from the Chronic Disease Research Foundation, the Medical Research Council (MRC), British Heart Foundation, the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based Healthcare, the Wellcome Flagship Programme (WT213038/Z/18/Z and Alzheimer's Society (AS-JF-17-011), and the Massachusetts Consortium on Pathogen Readiness (MassCPR).

Introduction

Vaccination against SARS-CoV-2 is a leading strategy to change the course of the pandemic world-wide. The United Kingdom was the first country internationally to authorise a vaccine against SARS-CoV-2 (1), with three vaccines currently licensed: BNT162b2 ("Pfizer-BioNTech"), mRNA-1273 ("Moderna") and ChAdOx1 nCoV-19 ("Oxford-AstraZeneca"), each with good efficacy in Phase 3 clinical trials (2-5). As of 14 May 2021, ~36.3 million (69%) of the UK adult population had received at least one vaccination (6). Thus, UK data presents one of the first windows not only on real-world efficacy but also on the remaining challenges post-vaccination.

Previous analysis of community-based individuals using the COVID Symptom Study app showed significant reduction in infection post-vaccination, from 12 days after first vaccine dose (7), findings recapitulated in a UK-based "real world" case-control study (8). Similarly, national surveillance data from the first four months of Israel's national vaccination campaign showed two doses of BNT162b2 prevented symptomatic and asymptomatic infections, COVID-19 related hospitalisations, severe disease, and death (9).

None-the-less, some individuals still contract COVID-19 after vaccination, and further virus variants may evolve with increased transmissibility (as with B 1.1.7 and B.1.617.2) (10, 11). Further, early data suggest that while COVID-19 is usually milder if contracted post-vaccination, mortality is still high in hospitalised individuals: data from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) from April 2021 showed mortality of 28% in individuals hospitalised with COVID-19 >21 days post-vaccination, similar to mortality rates during the first pandemic wave (March-April 2020) (12, 13).

Identifying and protecting individuals at higher risk of post-vaccination infection will become increasingly salient as a greater proportion of the population is vaccinated. Groups at higher risk of SARS-CoV-2 infection before vaccine availability include frontline healthcare workers and individuals from areas of greater relative deprivation (likely reflecting increased exposure) (14, 15); and increasing age, male sex, multi-morbidity and frailty are associated with poorer COVID-

19 outcomes (16-18). However, to our knowledge there are no studies investigating risk factors for post-vaccination infection.

Individuals with COVID-19 have varying symptoms and differing clinical needs (19). Elucidating symptom profiles in individuals with COVID-19 post-vaccination has clinical utility: facilitating identification of risk groups for intervention, predicting medical resource requirements and informing appropriate testing guidelines. Finally, some unvaccinated individuals with COVID-19 experience prolonged illness duration ('Long-COVID') (20). Whether this risk is similar in individuals infected post-vaccination is unknown.

The aims of this study were:

1. To describe individual factors associated with SARS-CoV-2 infection at least 14 days after first vaccination,
2. To assess illness duration, symptom profile and disease severity in individuals with SARS-CoV-2 infection after first vaccination compared to unvaccinated individuals with SARS-CoV-2 infection.

Methods

Study design and participants

This community-based case-control study used data from the COVID Symptom Study logged through a free smartphone app developed by Zoe Global (London, UK) and King's College London (London, UK) (21). The app was launched in the UK on 24 March 2020, with nearly 4.5 million unique participants providing data by self- or proxy-report. At registration, each participant reported baseline demographic information (e.g., age, sex, ethnicity, whether a healthcare worker) geographic location, and information on health risk factors including comorbitidies, lifestyle, frailty and visits to hospital. Participants were encouraged to self-report their experience of pre-specified symptoms daily, enabling prospective and longitudinal information on incident symptoms. Those experiencing new symptoms were prospectively encouraged to present for a SARS-CoV-2 test through local testing centres. All users were asked to record any COVID-19 testing results (whether prompted by the app or for other reasons), and from December 2020, any administered COVID-19 vaccine(s) and subsequent symptoms (21).

This study used a nested sub-population of individuals who first reported a positive test for SARS-CoV-2 after SARS CoV-2 vaccination (cases) and two control populations matched 1:1 to the cases, all drawn from app-users.

Inclusion criteria for cases were: 1) age ≥18 years; 2) living in the UK; 3) first dose of a COVID-19 vaccine received between 8 December 2020 and 1 May 2021; 4) at least 14 days of ongoing app usage after vaccination; 5) either a positive RT-PCR or lateral flow antigen test (LFAT) at least fourteen days after receiving first vaccine dose and not after the second dose (if more than one test result was reported, the first positive test was selected), with no previous positive test pre-vaccination.

To identify risk factors for post-vaccination infection, controls were vaccinated UK adults reporting negative RT-PCR or LFAT before second vaccination, and until 14 May 2021 (date of data extraction) (CG-1), matched 1:1 with cases for date of testing post-vaccination, healthcare worker status, and sex (using a matching algorithm based on minimum Euclidean distance (22) between the vectors of these covariates, with sex as a binary variable multiplied by 100 to ensure balance between covariate strengths). If multiple negative tests were reported, the last test date was used for matching.

To compare symptoms of SARS CoV-2 infection pre- and post-vaccination we selected controls aged ≥18 years, living in the UK, who were unvaccinated and reported a positive SARS-CoV-2 test, regardless of symptoms (CG-2). Controls were matched 1:1 with cases for the day of positive testing, healthcare worker status, sex, BMI, and age, using the method above.

In addition, data from all app users reporting a RT-PCR or LFAT test within the study period (n=1,531,762) were processed to obtain weights for inverse probability of being vaccinated.

Risk factor variable definition

To identify risk factors for testing positive vs. negative for SARS-CoV-2 infection at least 14 days after first vaccination we used case status (self-reported positive RT-PCR test or LFAT for SARS-CoV-2) as the outcome variable.

We assessed age, self-reported comorbidities (cancer, diabetes, asthma, lung disease, heart disease, and kidney disease) analysed individually as binary variables; dependency level (frailty), assessed by the PRISMA7 questionnaire (embedded in the app registration) (23, 24) and classified as a binary variable (PRISMA7 ≥ 3 = frail; PRISMA7 < 3 = not frail) (25); local area Index of Multiple Deprivation (IMD), a score, ranging from 1 (most deprived) to 10 (least deprived) providing an estimate of relative locality deprivation derived from postal code on registration, divided into low (1-3), middle (4-7), and high (8-10) groups (26); and a healthy lifestyle score based on four lifestyle factors (27) — no current smoking, no obesity (Body Mass Index<30), physical activity at least once weekly, and a healthier diet pattern (see Supplementary Methods).

Disease severity and symptom definitions

To compare COVID-19 symptoms and severity in vaccinated vs. unvaccinated individuals testing positive for SARS-CoV-2, we assessed: 1) disease severity, assessed as: asymptomatic/symptomatic; >5 symptoms/≤5 symptoms reported in the first week of illness (19); and self-reported presentation to hospital/no hospital presentation; 2) illness duration, assessed as duration <28days/ duration≥28days; 3) individual symptom reports. Exposure variable was vaccination status. For cases and CG-2, symptoms were considered within a window from three days before and up to fourteen days after test date for SARS-CoV-2 (see Supplementary Table 2 for complete list).

Statistical analyses

Data census was 14 May 2021. Data was extracted and preprocessed using ExeTera13, a Python library developed at KCL and openly available on GitHub (28). Statistical analysis was run using Python 3.7 and the following packages: numpy v1.19.2, pandas v1.1.3, scipy 1.5.2, and statsmodels v0.12.1.

Risk factor analysis

Differences in proportions and means of covariates between cases and respective controls were assessed using Fisher's exact test for categorical variables and Wilcoxon's test for continuous variables. Univariate logistic regression models adjusted for age, BMI, and sex were used to analyse association between each comorbidity, frailty status, IMD tertile, and environmental and lifestyle factors with post-vaccine infection. As factors associated may differ by age group, all analyses were stratified by sex and age (younger adults: 18-59 years; older adults, ≥60 years). Multivariable logistic regression adjusted for age, BMI, and sex was used to analyse the combined association of obesity, sedentary lifestyle, healthier diet, IMD tertile and frailty status with the probability of post-vaccine infection.

To examine whether health-conscious behaviour might explain the association of lifestyle factors and infection post-vaccination we adjusted models for reported individual adherence to mask wearing guidance during 2020. Finally, we examined models using inverse probability weighting (IPW) (29) to check for potential index event bias of vaccination using weights derived from probabilities of being vaccinated in the population active on the app in the study period (Supplementary Figure 2).

Analyses of reported symptoms

Univariate logistic regression models adjusted by age, BMI and sex were used to assess association of individual symptoms, overall illness duration, and disease severity (outcomes), with vaccination status (exposure). Symptoms were examined if reported by >1% of all app users with a positive test. We also provide models additionally adjusting for frailty and comorbidities, given their association with the exposure (vaccination) and outcome (symptomatology) which therefore may confound any observed associations.

This study reports on BNT162b2 and ChAdOx1 vaccines only, as there were no positive cases who received the mRNA-1273 vaccine. Post-vaccination infection was similar in these two vaccine types therefore combined analysis was performed.

Ethical approval

All app users provided informed consent for use of their data for COVID-19 research. In the UK, the app and study were approved by King's College London (KCL) ethics committee (REMAS no. 18210, review reference LRS-19/20–18210).

Role of the funding source

Funders did not have any role in design, analysis or interpretation of the data. Zoe Global, funded by DHSC, made the app available for data collection as a not-for-profit endeavour.

Results

Between 8 December 2020 and 14 May 2021, 1,102,192 app users reported receiving a first dose and 559,962 a second dose of a COVID-19 vaccine (approximately one-third BNT162b2, and two-thirds ChAdOx1). Of these, 2,394 (0.2%) and 187 (0.03%) reported testing positive for SARS-CoV-2 at least 14 days after first and second vaccination respectively. Supplementary Figure 1 shows time in days from the first or second dose and day of positive testing which also reflects changing incidence of COVID-19 infection in the UK population (30).

Risk/protective factor analysis

Table 1 shows demographic information of cases and controls for the risk factor analysis. More participants were female (69.5%). Cases were significantly younger and had higher BMI (p-value< 0.0001 for both variables). Asthma and lung disease were the most commonly reported comorbidities in both cases and controls; there was no significant difference in prevalence of comorbidities between cases and controls, overall or stratified by two age groups (Table 1). Cases were more likely to smoke and have a sedentary lifestyle, and less likely to have a healthier diet.

Multivariable analysis of age and BMI, adjusted for sex, showed a significant *inverse* association between age and post-vaccination infection, particularly in older adults (OR=0.96, 95% CI [0.95-0.97] per unit increase in age, p-value<0.0001, see Supplementary Table 1 for detailed results). We also observed a modest but significant positive relationship between BMI and post-vaccination infection especially in younger adults (OR=1.02, 95% CI [1.01-1.03] per unit increase in BMI, p<0.0001).

Table 1. Demographics of post-vaccination cases and controls for risk factor analysis

	Positive group			Control group 1: vaccinated users testing negative, matched on healthcare worker status, sex and day of test		
	All n=2394 BNT=1427 ChA=888 NS=79	**Younger adults (18-59 years) n=1372 BNT=871 ChA=446 NS=55**	**Older adults (60+ years) n=1022 BNT=556 ChA=442 NS=24**	**All n=2394 BNT=1477 ChA=762 NS=155**	**Younger adults (18-59 years) n=1467 BNT=951 ChA=384 NS=132**	**Older adults (60+ years) n=927 BNT=526 ChA=378 NS=23**
Basic characteristics						
Female n(%)	1663(69.5)	1037(75.6)	626(61.3)	1663(69.5)=	1136(77.4)=	527(56.9)*
Age (SD)	52.9(15.1)	42.7(9.1)	66.6(9.8)	54.8(15.5)*	45.0(10.2)*	70.3(7.9)*
BMI (SD)	27.6(7.0)	27.9(7.3)	27.2(6.6)	26.7(6.8)*	26.9(7.1)*	26.3(6.4)*
HCW n(%)	643(26.9)	459(33.5)	184(18.0)	642(26.8)=	561(38.2)*	81(8.7)*
Comorbidities						
Cancer n(%)	45(1.9)	7(0.5)	38(3.7)	51(2.1)=	10(0.7)=	41(4.4)=
Diabetes n(%)	97(4.1)	26(1.9)	71(6.9)	93(3.9)=	36(2.5)=	57(6.1)=
Lung disease n(%)	261(10.9)	148(10.8)	113(11.1)	258(10.8)=	180(12.3)=	78(8.4)*
Heart disease n(%)	119(5.0)	17(1.2)	102(10.0)	124(5.2)=	24(1.6)=	100(10.8)=
Kidney disease n(%)	35(1.5)	13(0.9)	22(2.2)	29(1.2)=	14(1.0)=	15(1.6)=
Asthma n(%)	348(14.5)	216(15.7)	132(12.9)	342(14.3)=	246(16.8)=	96(10.4)=
Frailty n (%)	162(6.8)	24(1.7)	138(13.5)	159(6.6)=	41(2.8)=	118(12.7)=
Comorbidity status	592(24.7)	280(20.4)	312(30.5)	604(25.2)=	322(21.9)=	282(30.4)=
IMD						
IMD [1-3] n(%)	528(22.1)	316(23.0)	212(20.7)	415(17.3)*	267(18.2)*	148(16.0)*
IMD [4-7] n(%)	947(39.6)	566(41.3)	381(37.3)	921(38.5)=	582(39.7)=	339(36.6)=
IMD [8-10] n(%)	919(38.4)	490(35.7)	429(42.0)	1058(44.2)*	618(42.1)*	440(47.5)*
Healthy lifestyle[1]						
No smoking n(%)	1211(97.1)	863(96.5)	339(98.5)	1226(98.3)=	701(97.6)=	516(99.2)=
Not obese n(%)	886(71.1)	621(69.5)	265(77.0)	1007(80.8)*	564(78.6)*	443(85.2)*
Healthier diet n(%)	422(33.8)	276(30.9)	140(40.7)	545(43.7)*	282(39.3)*	261(50.2)*
Not sedentary n(%)	952(76.3)	681(76.2)	265(77.0)	982(78.7)=	570(79.4)=	406(78.1)=
Healthy lifestyle score	2.8(0.9)	2.7(0.9)	2.9(0.9)	3.0(0.9)*	2.9(0.9)*	3.1(0.8)*

BMI=Body mass index; SD=Standard deviation; HCW=Healthcare worker; IMD=Index of Multiple Deprivation; IMD[1-3] indicates high deprivation, IMD [4-7] intermediate, IMD[8-10] low deprivation; age is in years; comorbidity status=at least one comorbidity; for age and BMI the mean and standard deviation are provided, and for categorical variables the absolute value and percentages (%).

[1]For the analysis on the healthy lifestyle factor only part of the study population (n=1247) answered the diet questionnaire; the other users were not included in the analysis

*/= Indicates statistically significant/no statistically significant difference when compared to the case population (Fisher's $p<0.05$)

Among older adults, frailty was strongly associated with post-vaccination infection (OR=2.78, 95% CI [1.98-3.89], p-value<0.0001, Figure 1a and Supplementary Table 2 for detailed results). When examining associations between each individual comorbidity and post-vaccination infection, no factors were associated overall or in younger adults; however, in older adults kidney disease was associated with post-vaccination infection (OR=2.10, 95% CI [1.05-4.21], p-value=0.037). These findings were consistent following a sensitivity analysis using inverse probability weighting for factors influencing vaccination (Supplementary Table 3).

Users living in areas of lowest deprivation (IMD[8-10]) and highest deprivations showed respectively lower and higher risk compared to the intermediate category (IMD[4-7]) reflecting a progressive increase in risk of post-vaccination infection for individuals living in more deprived areas (IMD[8-10] OR=0.87, 95% CI [0.76-0.98], p-value=0.026; IMD [1-3] OR=1.22, 95% CI [1.04-1.43], p-value=0.013). Both relations appeared stronger in younger adults than in older adults (see Figure 1b and Supplementary Table 4 for detailed results).

Healthier lifestyle factors were generally associated with lower odds of infection after vaccination regardless of age group. Younger adults with healthier lifestyles had lower odds of post-vaccination infection, per each additional lifestyle factor (OR=0.77, 95% CI [0.68-0.88], p-value<0.0001). The strongest association was seen for body mass (normal weight OR=0.54, 95% CI [0.37-0.78], p-value=0.001). Results were similar in older adults, except for obesity which was no longer significant (see Figure 1b and Supplementary Table 4).

Figure 2 shows the multivariable analysis considering non-obesity, non-sedentary behaviour, non-smoking, healthy diet, IMD, and frailty, adjusted for age, BMI, and sex (see Supplementary Table 5 for detailed results). Frailty remained significantly associated with infection risk in older adults, after adjustment for environmental and lifestyle factors (OR = 2.45, 95% CI [1.09-5.52], p=0.03, Supplementary Table 5). Healthier diet and having non-obese weight were independently associated with reduced risk of post-vaccine infection in younger adults. The above findings were consistent in a sensitivity analysis using inverse probability weighting for factors influencing vaccination (see Supplementary Tables 6 and 7 for univariate and multivariate analysis results, respectively).

Figure 1. Odds ratio of COVID-19 infection after vaccination: a) Univariate models for frailty and each individual comorbidity, adjusted for age, body mass index (BMI) and sex and stratified by age-group; b) Univariate models for environmental (IMD category), obesity status and healthy lifestyle factors, adjusted for age, BMI, and sex and stratified by age-group.

a)



b)



BMI = Body Mass Index; IMD = Index of Multiple Deprivation. IMD[1-3]=high deprivation, IMD[8-10]=low deprivation; reference category for IMD is IMD [4-7] = intermediate category.

Figure 2. Multivariable analysis of frailty, IMD category, obesity status and healthy lifestyle factors, adjusted for age, BMI and sex.



BMI = Body Mass Index; IMD = Index of Multiple Deprivation. IMD[1-3]=high deprivation, IMD[8-10]=low deprivation; reference category for IMD is IMD [4-7] = intermediate category.

Illness profile in vaccinated and unvaccinated individuals with SARS-CoV-2 infection

2188 cases met the inclusion criteria and were followed-up for at least 14 days post-vaccination (median duration of follow-up is 77 days, first and third quartile equal to 41 and 101 days, respectively). These were matched 1:1 to 2188 unvaccinated controls using nearest Euclidean distance as per methods, which resulted in a ~20% preponderance of health care workers in the case group (Table 2). Vaccinated individuals were less likely to have multiple (>5) symptoms in the first week of illness (OR=0.51, 95%CI=[0.42-0.61], p-value<0.0001), attend hospital (OR=0.36, 95%CI [0.28-0.46] p-value<0.0001), and were more likely to be completely asymptomatic (OR=1.72, 95%CI [1.41-2.11], p-value<0.0001 Figure 3, Supplementary Table 8). For older adults, there were lower odds of symptoms continuing for more than 28 days (OR=0.72, 95%CI [0.51-1.00], p-value=0.05), although this was not significant in younger adults. Analysis of individual symptoms (Figure 4 and Supplementary Table 9), showed that vaccination was associated with lower symptom reporting for almost all symptoms across all age groups, with the exceptions of shortness of breath, earache and swollen glands (no significant difference in vaccinated vs. unvaccinated individuals) and sternutation (sneezing; more common in vaccinated individuals (OR=1.24 95%CI [1.05-1.46], p-value=0.01, Figure 4 and Supplementary Table 9). Analyses were unchanged after adjustment for comorbidities and frailty (Supplementary Tables 9 and 10).

Table 2. Demographics of vaccinated and unvaccinated adults with SARS-CoV 2 infection used for symptom analysis

	Positive group			Control group of unvaccinated users testing negative (HCW-, sex-, day_of_test-, age-, and BMI-matched)		
	All (n=2188,BNT=1363, ChA=748, NS=77)	Younger adults[18-59 years] (n=1248, BNT=837, ChA=356, NS=55)	Older adults [60+ years] (n=940, BNT=526, ChA=392,NS=22)	All (n=2188)	Younger adults [18-59 years] (n=1260)	Older adults [60+ years] (n=928)
Basic characteristics						
Female n(%)	1533(70.1)	957(23.3)	576(38.7)	1542(70.5)=	961(23.7)=	581(37.4)=
Age (SD)	53.0(15.4)	42.5(9.2)	66.9(10.0)	52.8(15.2)*	42.6(9.2)=	66.8(9.8)=
BMI (SD)	27.7(7.1)	27.9(7.4)	27.3(6.8)	27.6(7.0)=	27.9(7.3)=	27.3(6.5)=
HCW n(%)	624(28.5)	445(35.7)	179(19.0)	489(22.3)*	351(27.9*)	138(14.9)*
Frailty n (%)	156(7.1)	19(1.5)	137(14.6)	114(5.2)*	20(1.6)=	94(10.1)*
Comorbidity status n(%)	547(25.0)	255(20.4)	292(31.1)	513(23.4)=	232(18.4)=	281(30.3)=
Asymptomatic infection n(%)	298(14.2)	119(10.0)	179(19.7)	173(8.8)*	75(6.6)*	98(11.8)*
Hospitalised n(%)	104(4.8)	39(3.2)	65(7.0)	239(11.4)*	76(6.3)*	163(18.3)*
>5 reported symptoms n(%)	242(15.6)	139(17.6)	103(13.6)	340(29.5)*	195(31.5)*	145(27.1)*
symptoms lasting >28 days n(%)	134(8.7)	58(7.3)	76(10.0)	124(10.7)*	42(6.8)=	82(15.3)*

BMI=Body mass index; SD=Standard deviation; HCW=Healthcare worker; n=number of individuals; age is in years; Comorbidity status=users with at least one comorbidity; BNT=BNT162b2; ChA=ChAdOx1; NS=not sure; for age and BMI the mean and standard deviation are provided and for categorical variables the absolute value and percentages (%); severity is equal to one if the sum of symptoms experienced in the first week >5.

*/= Indicates statistically significant/no statistically significant difference when compared to the case population (Fisher's $p<0.05$)

Figure 3. Odds ratio of asymptomatic infection, duration of symptoms > 28 days, severe disease (> 5 reported symptoms during acute infection) and hospitalisation in app participants following vaccination, adjusted by (i) age, BMI and sex and (ii) age, BMI and sex, frailty and comorbidity status.



Figure 4. Odds Ratio of individual symptoms in vaccinated versus unvaccinated app participants with reported SARS-CoV-2 infection, adjusted by (i) age, BMI and sex and (ii) age, BMI, sex, frailty and comorbidity status.



Discussion

As countries around the world vaccinate their populations against COVID-19, there is growing interest in understanding risk factors for and characteristics of post-vaccination infection. Health policies and resource planning in the post-vaccination era need to be guided by evidence of who is most at risk of infection, to reduce morbidity and mortality whilst considering the adverse effects of shielding and isolation on quality of life and health. Here, we present data on 2,394 community-based adults in the UK who developed test-confirmed SARS-CoV-2infection more than 14 days after first vaccination with either BNT162b2 or ChAdOx1. By 14 days, immunity is starting to develop (31); and infection is unlikely to be due to exposure peri-vaccination (e.g. during travel to the vaccination centre).

Frail individuals had higher odds of post-vaccine COVID-19 infection than matched controls, highlighting the need for ongoing caution in this vulnerable group. The association was neither diminished by inverse probability weighting for factors influencing vaccination, nor when adjusting for possible confounders such as local area deprivation or lifestyle factors. This finding may, in part, reflect increased exposure: whilst robust older adults may shield (see below), frailer adults may need home care visits or to attend healthcare facilities. Frail adults residing in long-term care are at particular risk of transmission of respiratory illness, and such facilities have been disproportionately affected throughout the pandemic (32). A second explanation may be altered immune function, or "immunosenescence", a well-established feature of physiological ageing, thought responsible (at least in part) for increased incidence and severity of infection with increasing biological age (33). Immunosenescence may also be responsible for previously observed ageing-associated decline in immunogenicity following vaccination for other infections (34). The increased odds of post-vaccine infection in frailer adults may be compounded by more severe outcomes of COVID-19 infection in this group, including delirium (24) and death (17). NICE recommend systematic frailty assessment in acute settings, (https://www.nice.org.uk/guidance/NG159), and this should be extended to community settings to facilitate a differential, targeted re-vaccination scheduling, appropriate isolation precautions, case detection, testing and proactive care in this risk group. Research on augmentation of the immune response to vaccination in this group is urgently needed; for example, the impact and timing of booster vaccinations, and appropriate timing for this, could be assessed.

We found an inverse association of age on odds of post-vaccination infection, especially in older adults. Reduced risk of infection in older adults is consistent with previous studies in non-vaccinated individuals showing lower antibody seroprevalence in older adults (35); this likely reflects shielding in this age-group in accordance with government classification of over 70s as clinically vulnerable (36). We found some evidence that kidney disease may increase the odds of infection post-vaccination. This is potentially important, as patients with kidney disease were under-represented in the Phase 2 and Phase 3 trials of vaccines (37). This may reflect increased exposure (e.g. unavoidable attendance at dialysis, despite otherwise shielding), or may reflect impaired immune responses to vaccination in these individuals as already observed for other infections (38, 39). We also note early evidence suggesting reduced immune response in

individuals taking anti-cancer therapy, with suggestions that augmentation with a third vaccine may be appropriate (40). In our cohort, neither report of cancer nor other comorbidities were significantly associated with an increased odds of infection. While this is reassuring, given that the comorbidities assessed here conferred higher risk of severe disease, hospitalisation, mechanical ventilation, and mortality from COVID-19 (16, 41), as with age, ongoing shielding behaviours in these groups may be influencing our results.

Greater area level deprivation was strongly associated with risk of post-vaccination SARS-CoV-2 infection, despite correction for other risk factors. This association persisted following adjustment for compliance with guidance on infection control (specifically, mask-wearing). People living in areas of higher deprivation had increased odds of testing positive for COVID-19 relative to those lower deprivation (42). Associated factors such as higher population density, and more ethnically diverse populations are all also associated with higher mortality from COVID-19 (43, 44). Individuals in more deprived areas also have lower vaccination coverage for COVID-19 (45), and therefore our finding may reflect increased viral transmission in these areas. The current study highlights that disproportionate risk in high deprivation areas may still apply post-vaccination; health policies to mitigate infection will need to be targeted to these areas.

Conversely, this study found that individuals with healthier lifestyles had lower risk of infection post-vaccination. In particular, people reporting a healthier diet were observed to have lower risk of post-vaccination infection. In addition, those without obesity had reduced risk. BMI has been associated with increased risk of hospitalisation and death from COVID-19 (44). The current study suggests that immune responses post-vaccination may also be influenced by diet quality and obesity. This may in part be due to unadjusted confounding with protective healthy behaviours, including continued adherence to infection control advice post-vaccination; however, the effect was robust when adjusted for compliance with mask-wearing guidance.

Comparing symptoms in vaccinated vs. unvaccinated adults with COVID-19, almost all individual symptoms of COVID-19 disease were less common in the vaccinated population. The exception was sternutation (sneezing), which was reported more commonly in younger adults who contracted infection post-vaccination. We are unaware of previous reports of sneezing being more common post-vaccination for other respiratory illnesses but it is a well-recognised symptom of both

respiratory infection and allergy prompted by nasal mucosa irritation. In the context of allergy, activation of the immune system can heighten the sneeze response to an antigen through inflammatory cascades including cytokine production and neuropeptides (46); thus immune system 'priming' with vaccination might lead to an increase in sneezing in the context of new infection, which would constitute an appropriate adaptive response. While the risk of infection with, and transmission of, SARS-CoV-2 is lower in vaccinated compared to unvaccinated individuals (8), sneezing generates aerosols; potentially of importance for viral transmission in the post-vaccine era. Policy implications might include guidance for individuals interacting with unvaccinated or vulnerable groups to test for SARS-CoV-2 if they experience new unexplained sneezing even if they have been vaccinated.

We found that severity of COVID-19 (both number of symptoms in the first week of infection, and need for hospitalisation) and duration was lower in vaccinated compared to unvaccinated individuals. The odd ratios for being hospitalised or having >5 symptoms in the first week were 0.36 [0.28-0.46] and 0.51 [0.42-0.61] respectively. We have previously shown that experiencing more than 5 symptoms in the acute period was associated both with severity of disease (19) and duration of symptoms (20). In the 60+ group, we found lower risk of symptoms lasting for more than 28 days (OR=0.72, 95%CI [0.51-1.00]). Put together, this suggests that severe acute disease is likely to be less common in those who are vaccinated. In the age group most commonly affected by Long-COVID, this consequence may also be less prevalent. However, while absolute numbers of hospitalisations may reduce, early data suggests that mortality in hospitalised patients who contracted COVID-19 after vaccination remains high (12). Our data would suggest that this may relate to increased risk of post-vaccination infection in older people who are frail.

Strengths and Limitations

This study used data from a large population of individuals reporting on a mobile application. This population, while large, was disproportionately female and under-represented individuals of lower socio-economic status as indicated by the skew toward people living in less deprived areas (Table 1).

Information was self-reported and therefore recording of comorbidities and test results may not be completely accurate. However, previous data from this study have concurred well with population-

based COVID-19 studies(47), including the influence of socio-demographic factors (42). A strength of the mobile data collection method is the ability to collect daily information prospectively, on a comprehensive set of symptoms, allowing analysis of both individual symptoms and overall illness duration. We acknowledge also that by virtue of data censoring dates, symptom duration may be underestimated in both cases and controls, as some individuals only had two weeks of logging after their positive test result .

The design of our study, including matching cases and controls for health-care worker status and time of infection, reduces potential for collider bias, although small differences between the groups remained on matched variables. Risk of reporting a positive SARS-CoV-2 test is higher amongst frontline healthcare workers vs. the general population (14), reflecting exposure; and - appropriately - healthcare workers were prioritised for vaccination in the UK (48). Our data suggests risk of post-vaccination SARS-CoV-2 infection is reduced in older age groups. In order to examine the effect of age on post-vaccination infection, we did not match CG1 by age. However, age was included as a covariate in all analyses other than that looking at effects of age itself, and stratified analyses are presented in two age-groups. While vaccination itself might be considered a potential index event bias, the population of interest in this study is the vaccinated population, and should not be construed as applying to those unvaccinated. Nevertheless, we examined and found no evidence of event bias based on probability of being vaccinated.

Frailty was assessed with the PRISMA-7 questionnaire for app usage. This assessment correlates well with other frailty measures (49) and has the advantage of focusing on functional consequences of frailty, not routinely captured in health records. However, PRISMA-7 has only been validated in older adults; results in younger adults should be interpreted cautiously (23).

Finally, this study was conducted at the beginning of the post-vaccination period, at a time when incidence of SARS-CoV-2 infection in the UK was rapidly falling. In accordance with recently published ISARIC data, we saw declining incidence of new infections with time after vaccination (12), which may reflect both increasing immunity and dropping incidence in the population. Our findings may not apply at all time points post-vaccination. Lastly, the small number of individuals who had received a second vaccination precluded study of post-vaccination infection after more than one dose.

Conclusions

We investigated factors associated with increased risk of infection after vaccination and found a substantial increased risk in frail older adults and in individuals living in more deprived areas, and a lower risk of infection in non-obese people and those who reported better diet quality. We found most symptoms post-vaccination were reported less in vaccinated people, except sneezing. Need for hospital assessment was less, and burden of acute symptoms was lower. For older adults, risk of prolonged illness was lower. Our findings may inform policy in the post-vaccination era, in particular with regards to protecting frail older adults, and those individuals living in areas of higher relative deprivation. This research suggests focused infection control measures should continue to be in place for these populations, to minimise their risk of COVID-19, while strategies, such as booster vaccination, are explored.

Acknowledgements

Zoe Global provided in-kind support for all aspects of building, running and supporting the app and service to all users worldwide. This work is supported by the UK Department of Health via the National Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and King's College Hospital NHS Foundation Trust, and a grant to ZOE Globals, as well as by the Wellcome EPSRC Centre for Medical Engineering at King's College London (WT 203148/Z/16/Z). This work was further supported by the UK Research and Innovation London Medical Imaging & Artificial Intelligence Centre for Value-Based Healthcare. Investigators also received support from the Wellcome Trust, Medical Research Council (MRC), British Heart Foundation (BHF), Alzheimer's Society, European Union, NIHR, Chronic Disease Research Foundation (CDRF) and the NIHR-funded BioResource, Clinical Research Facility and Biomedical Research Centre (BRC) based at GSTT NHS Foundation Trust in partnership with KCL. S.O. was supported by the French government, through the 3IA Côte d'Azur Investments in the Future project managed by the National Research Agency (ANR) with the reference number ANR-19-P3IA-0002. A.T.C. was supported by a Stuart and Suzanne Steele MGH Research Scholar Award and by the Massachusetts Consortium on Pathogen Readiness (MassCPR) and M.

Schwartz and L. Schwartz. J.M. was partially supported by the European Commission Horizon 2020 program (H2020-MSCA-IF-2015-703787).

Supplementary Table 1. Multivariable analysis of age and body mass index (BMI), adjusted by sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
BMI	1.02	[1.01-1.03]	<0.0001	1.02	[1.01-1.03]	<0.0001	1.02	[1.00-1.02]	0.04
Age	0.99	[0.99-1.00]	<0.0001	0.97	[0.97-0.98]	<0.0001	0.96	[0.94-0.97]	<0.0001

OR = Odds ratio; CI = Confidence interval; BMI = Body mass index

Supplementary Table 2. Univariate analysis of frailty status and each comorbidity, adjusted by age, BMI, and sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
Frailty	1.21	[0.94-1.54]	0.133	0.59	[0.35-1.00]	0.05	2.78	[1.98-3.89]	<0.0001
Kidney disease	1.28	[0.78-2.12]	0.328	1.04	[0.48-2.24]	0.924	2.10	[1.05-4.21]	0.037
Lung disease	0.98	[0.82-1.18]	0.843	0.83	[0.66-1.05]	0.130	1.35	[0.99-1.84]	0.057
Heart disease	1.08	[0.83-1.42]	0.558	0.83	[0.44-1.56]	0.563	1.31	[0.96-1.79]	0.095
Diabetes	1.01	[0.75-1.36]	0.932	0.71	[0.42-1.19]	0.191	1.21	[0.83-1.77]	0.324
Asthma	0.98	[0.84-1.16]	0.834	0.90	[0.73-1.10]	0.293	1.26	[0.95-1.67]	0.114
Cancer	1.01	[0.67-1.52]	0.972	0.93	[0.35-2.47]	0.891	1.15	[0.72-1.85]	0.550

OR = Odds ratio; CI = Confidence interval

Supplementary Table 3. Sensitivity analysis of frailty and each comorbidity using Inverse Probability Weighting (IPW) for probability of vaccination. Each univariate analysis is adjusted by age, BMI, and sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
Frailty	1.15	[0.93-1.43]	0.189	0.55	[0.37-0.82]	0.003	3.06	[2.20-4.25]	<0.0001
Kidney disease	1.06	[0.67-1.67]	0.818	0.84	[0.44-1.61]	0.607	1.84	[0.95-3.55]	0.07
Lung disease	0.99	[0.86-1.15]	0.933	0.81	[0.68-0.97]	0.018	1.5	[1.11-2.02]	0.008
Heart disease	1.05	[0.82-1.34]	0.718	0.8	[0.48-1.34]	0.396	1.3	[0.96-1.75]	0.084
Diabetes	0.87	[0.67-1.14]	0.327	0.63	[0.41-0.96]	0.031	1.01	[0.71-1.45]	0.939
Asthma	0.98	[0.86-1.12]	0.748	0.89	[0.76-1.03]	0.116	1.27	[0.97-1.66]	0.084
Cancer	0.89	[0.60-1.32]	0.56	0.9	[0.42-1.95]	0.794	1.01	[0.64-1.62]	0.951

OR = Odds ratio; CI = Confidence interval

Supplementary Table 4. Univariate analysis of Index of Multiple Deprivation (IMD) category, obesity status and healthy lifestyle factors, adjusted by age, BMI, and sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
IMD[1-3]	1.22	[1.04-1.43]	0.013	1.21	[0.99-1.48]	0.062	1.25	[0.96-1.63]	0.091
IMD[8-10]	0.87	[0.76-0.98]	0.026	0.86	[0.72-1.01]	0.071	0.86	[0.71-1.06]	0.155
Healthy lifestyle score	0.79	[0.71-0.88]	<0.0001	0.77	[0.68-0.88]	<0.0001	0.8	[0.66-0.98]	0.026
Healthier diet	0.73	[0.62-0.86]	<0.0001	0.73	[0.59-0.90]	0.003	0.71	[0.54-0.95]	0.02
Not obese	0.6	[0.44-0.82]	0.001	0.54	[0.37-0.78]	0.001	0.81	[0.47-1.40]	0.45
Non-smoker	0.64	[0.37-1.12]	0.118	0.69	[0.38-1.26]	0.224	0.57	[0.15-2.22]	0.419
Non-sedentary	0.9	[0.74-1.09]	0.272	0.85	[0.67-1.09]	0.195	0.93	[0.65-1.31]	0.664

OR = Odds ratio; CI = Confidence interval; IMD[1-3] = high deprivation, IMD[8-10] = low deprivation; reference category for IMD is the intermediate category IMD [4-7]

Supplementary Table 5. Multivariable analysis of frailty, IMD category, obesity status and healthy lifestyle factors, adjusted for age, BMI and sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Frailty	1.02	[0.59-1.77]	0.94	0.55	[0.26-1.18]	0.12	2.45	[1.09-5.52]	0.03
IMD[1-3]	1.18	[0.94-1.49]	0.16	1.25	[0.94-1.65]	0.13	1.03	[0.67-1.59]	0.88
IMD[8-10]	0.82	[0.69-0.98]	0.03	0.78	[0.62-0.97]	0.03	0.87	[0.64-1.19]	0.39
Healthy lifestyle score	0.75	[0.63-0.89]	0.00	0.76	[0.61-0.94]	0.01	0.71	[0.53-0.95]	0.02
Healthier diet	0.62	[0.46-0.84]	0.00	0.57	[0.39-0.83]	0.00	0.78	[0.45-1.36]	0.39
Not obese	0.69	[0.40-1.21]	0.20	0.75	[0.41-1.39]	0.36	0.60	[0.15-2.37]	0.47
Non-smoker	0.98	[0.80-1.20]	0.85	0.93	[0.72-1.19]	0.54	1.02	[0.71-1.46]	0.91

OR = Odds ratio; CI = Confidence interval; IMD = Index of Multiple Deprivation;IMD[1-3] = high deprivation, IMD[8-10]= low deprivation; reference category for IMD is the intermediate category IMD [4-7]

Supplementary Table 6. Sensitivity analysis of univariate analyses for IMD categories, obesity status and healthy lifestyle factors, using Inverse Probability Weighting (IPW) for probability of vaccination. Each univariate analysis is adjusted for age, BMI, and sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
IMD[1-3]	1.32	[1.15-1.51]	<0.0001	1.30	[1.12-1.51]	0.001	1.490	[1.11-1.99]	0.008
IMD[8-10]	0.87	[0.79-0.96]	0.006	0.83	[0.74-0.94]	0.002	0.860	[0.71-1.03]	0.105
Healthy lifestyle score	0.78	[0.72-0.85]	<0.0001	0.76	[0.69-0.84]	<0.0001	0.790	[0.66-0.94]	0.010
Healthier diet	0.72	[0.63-0.82]	<0.0001	0.67	[0.57-0.78]	<0.0001	0.700	[0.53-0.91]	0.008
Not obese	0.61	[0.48-0.77]	<0.0001	0.54	[0.41-0.70]	<0.0001	0.830	[0.49-1.40]	0.490
Non-smoker	0.61	[0.40-0.93]	0.023	0.64	[0.42-0.98]	0.038	0.610	[0.18-2.10]	0.430
Not sedentary	0.89	[0.76-1.04]	0.148	0.90	[0.76-1.08]	0.255	0.890	[0.64-1.23]	0.467

OR = Odds ratio; CI = Confidence interval; IMD = Index of Multiple Deprivation;;IMD[1-3] = high deprivation, IMD[8-10]= low deprivation; reference category for IMD is the intermediate category IMD [4-7]

Supplementary Table 7. Sensitivity analysis of the multivariable model for frailty, IMD categories, obesity status and healthy lifestyle factors. The analysis is adjusted by age, BMI, and sex

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
Frailty	0.77	[0.48-1.24]	0.28	0.37	[0.19-0.72]	0.00	2.08	[1.05-4.11]	0.04
IMD[1-3]	1.33	[1.09-1.61]	0.01	1.30	[1.03-1.65]	0.03	1.38	[0.95-2.01]	0.10
IMD[8-10]	0.82	[0.71-0.94]	0.01	0.77	[0.65-0.92]	0.00	0.87	[0.69-1.11]	0.28
Healthier diet	0.74	[0.65-0.85]	0.00	0.73	[0.62-0.87]	0.00	0.72	[0.57-0.91]	0.01
Not obese	0.63	[0.49-0.80]	0.00	0.56	[0.42-0.75]	0.00	0.84	[0.54-1.32]	0.45
Non-smoker	0.69	[0.45-1.05]	0.08	0.73	[0.46-1.16]	0.18	0.64	[0.23-1.82]	0.40
Not sedentary	0.98	[0.84-1.15]	0.83	0.95	[0.78-1.16]	0.61	1.00	[0.75-1.34]	0.98

OR = Odds ratio; CI = Confidence interval; IMD = Index of Multiple Deprivation;;IMD[1-3] = high deprivation, IMD[8-10]= low deprivation; reference category for IMD is the intermediate category IMD [4-7]

Supplementary Table 8. Univariate analysis assessing the probability of asymptomatic infection, severe disease (> 5 reported symptoms during acute infection), hospitalisation and duration of symptoms > 28 days in app participants following vaccination, adjusted by age, BMI, and sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
Hospitalisation	0.36	[0.28-0.46]	<0.0001	0.48	[0.32-0.71]	<0.0001	0.29	[0.21-0.39]	<0.0001
> 5 reported symptoms	0.51	[0.42-0.61]	<0.0001	0.52	[0.40-0.67]	<0.0001	0.49	[0.37-0.65]	<0.0001
symptoms lasting >28 days	0.89	[0.69-1.15]	0.379	1.19	[0.79-1.81]	0.407	0.72	[0.51-1.00]	0.050
Asymptomatic infection	1.72	[1.41-2.11]	<0.0001	1.59	[1.17-2.15]	0.003	1.84	[1.41-2.41]	<0.0001

OR = Odds ratio; CI = Confidence interval;

Supplementary Table 9. Univariate analysis assessing the probability of asymptomatic infection, severe disease (> 5 reported symptoms during acute infection), hospitalisation and duration of symptoms > 28 days in app participants following vaccination, adjusted by age, BMI, sex, frailty and comorbidity status.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
Hospitalisation	0.33	[0.26-0.43]	<0.0001	0.47	[0.31-0.70]	<0.0001	0.27	[0.19-0.38]	<0.0001
> 5 reported symptoms	0.53	[0.44-0.65]	<0.0001	0.54	[0.41-0.70]	<0.0001	0.52	[0.38-0.70]	<0.0001
symptoms lasting >28 days	1.01	[0.77-1.31]	0.971	1.31	[0.86-1.99]	0.212	0.82	[0.58-1.15]	0.254
Asymptomatic infection	1.72	[1.41-2.11]	<0.0001	1.59	[1.17-2.15]	0.003	1.85	[1.41-2.42]	<0.0001

OR = Odds ratio; CI = Confidence interval;

Supplementary Table 10. Univariate analysis assessing the probability of experiencing each symptom in app participants following vaccination, adjusted by age, BMI, sex.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**	**OR**	**95% CI**	**p-value**
Fever	0.31	[0.27-0.36]	<0.0001	0.37	[0.30-0.44]	<0.0001	0.24	[0.19-0.30]	<0.0001
Persistent cough	0.72	[0.63-0.82]	<0.0001	0.78	[0.65-0.92]	0.004	0.64	[0.52-0.78]	<0.0001
Loss of smell	0.53	[0.46-0.60]	<0.0001	0.54	[0.46-0.64]	<0.0001	0.5	[0.40-0.61]	<0.0001
Fatigue	0.45	[0.40-0.51]	<0.0001	0.49	[0.41-0.58]	<0.0001	0.4	[0.33-0.49]	<0.0001
Headache	0.52	[0.46-0.59]	<0.0001	0.5	[0.42-0.60]	<0.0001	0.53	[0.43-0.64]	<0.0001
Runny nose	0.68	[0.60-0.76]	<0.0001	0.79	[0.67-0.93]	0.005	0.54	[0.44-0.65]	<0.0001
Sneezing	1.1	[0.97-1.25]	0.136	1.24	[1.05-1.46]	0.011	0.92	[0.76-1.13]	0.449
Sore throat	0.58	[0.51-0.66]	<0.0001	0.58	[0.49-0.69]	<0.0001	0.58	[0.47-0.71]	<0.0001
Dizziness or lightheadedness	0.63	[0.55-0.73]	<0.0001	0.62	[0.52-0.74]	<0.0001	0.66	[0.53-0.82]	<0.0001
Chills or shivers	0.49	[0.42-0.56]	<0.0001	0.49	[0.40-0.59]	<0.0001	0.49	[0.39-0.60]	<0.0001

Hoarse voice	0.66	[0.57-0.76]	<0.0001	0.62	[0.52-0.75]	<0.0001	0.71	[0.57-0.89]	0.003
Skipped meals	0.47	[0.40-0.55]	<0.0001	0.57	[0.46-0.69]	<0.0001	0.36	[0.29-0.46]	<0.0001
Brain fog	0.74	[0.64-0.86]	<0.0001	0.76	[0.63-0.91]	0.003	0.72	[0.56-0.92]	0.009
Unusual muscle pains	0.64	[0.55-0.74]	<0.0001	0.63	[0.52-0.76]	<0.0001	0.65	[0.50-0.84]	0.001
Eye soreness	0.63	[0.54-0.73]	<0.0001	0.65	[0.54-0.79]	<0.0001	0.58	[0.45-0.75]	<0.0001
Diarrhoea	0.47	[0.40-0.56]	<0.0001	0.51	[0.41-0.63]	<0.0001	0.43	[0.33-0.55]	<0.0001
Shortness of breath	0.9	[0.77-1.06]	0.212	0.95	[0.77-1.17]	0.631	0.82	[0.63-1.07]	0.147
Low mood	0.61	[0.52-0.72]	<0.0001	0.65	[0.53-0.81]	<0.0001	0.56	[0.43-0.72]	<0.0001
Chest pain	0.8	[0.68-0.95]	0.009	0.78	[0.64-0.96]	0.017	0.85	[0.64-1.13]	0.257
Nausea	0.49	[0.42-0.59]	<0.0001	0.56	[0.45-0.70]	<0.0001	0.41	[0.31-0.54]	<0.0001
Tinnitus	0.72	[0.61-0.86]	<0.0001	0.75	[0.59-0.94]	0.013	0.69	[0.52-0.91]	0.009
Abdominal pain	0.61	[0.51-0.73]	<0.0001	0.6	[0.47-0.75]	<0.0001	0.64	[0.48-0.85]	0.002
Earache	0.85	[0.70-1.03]	0.091	0.92	[0.73-1.15]	0.449	0.72	[0.51-1.01]	0.06
Swollen glands	0.82	[0.67-0.99]	0.04	0.79	[0.63-1.00]	0.05	0.87	[0.62-1.23]	0.441
Sensation of skin burning	0.43	[0.35-0.53]	<0.0001	0.45	[0.34-0.58]	<0.0001	0.41	[0.28-0.58]	<0.0001
Delirium or reported confusion	0.64	[0.52-0.79]	<0.0001	0.56	[0.43-0.74]	<0.0001	0.73	[0.53-1.00]	0.05
Irregular heartbeat	0.61	[0.49-0.76]	<0.0001	0.66	[0.51-0.87]	0.003	0.51	[0.35-0.75]	0.001

OR = Odds ratio; CI = Confidence interval

Supplementary Table 11. Univariate analysis assessing the probability of experiencing each symptom in app participants following vaccination, adjusted by age, BMI, sex, frailty and comorbidity status.

	All age groups			Younger adults (18-59 years)			Older adults (60+ years)		
	OR	95% CI	p-value	OR	95% CI	p-value	OR	95% CI	p-value
Fever	0.31	[0.27-0.36]	<0.0001	0.36	[0.30-0.44]	<0.0001	0.24	[0.19-0.30]	<0.0001
Persistent cough	0.71	[0.62-0.81]	<0.0001	0.77	[0.65-0.92]	0.004	0.64	[0.52-0.79]	<0.0001
Loss of smell	0.53	[0.46-0.60]	<0.0001	0.54	[0.46-0.64]	<0.0001	0.5	[0.40-0.61]	<0.0001
Fatigue	0.45	[0.40-0.51]	<0.0001	0.49	[0.41-0.58]	<0.0001	0.4	[0.33-0.49]	<0.0001
Headache	0.52	[0.46-0.60]	<0.0001	0.5	[0.42-0.60]	<0.0001	0.53	[0.44-0.65]	<0.0001
Runny nose	0.68	[0.60-0.77]	<0.0001	0.79	[0.67-0.93]	0.005	0.54	[0.45-0.66]	<0.0001
Sneezing	1.12	[0.98-1.27]	0.087	1.25	[1.06-1.47]	0.009	0.95	[0.78-1.17]	0.636
Sore throat	0.59	[0.51-0.67]	<0.0001	0.58	[0.49-0.69]	<0.0001	0.58	[0.47-0.72]	<0.0001
Dizziness or lightheadedness	0.63	[0.55-0.73]	<0.0001	0.62	[0.51-0.74]	<0.0001	0.66	[0.53-0.82]	<0.0001
Chills or shivers	0.49	[0.42-0.56]	<0.0001	0.48	[0.40-0.58]	<0.0001	0.49	[0.39-0.60]	<0.0001
Hoarse voice	0.66	[0.57-0.76]	<0.0001	0.62	[0.52-0.75]	<0.0001	0.72	[0.58-0.90]	0.003
Skipped meals	0.46	[0.39-0.53]	<0.0001	0.56	[0.46-0.69]	<0.0001	0.35	[0.28-0.44]	<0.0001
Brain fog	0.73	[0.63-0.85]	<0.0001	0.75	[0.62-0.90]	0.003	0.69	[0.54-0.89]	0.004
Unusual muscle pains	0.63	[0.54-0.73]	<0.0001	0.63	[0.52-0.76]	<0.0001	0.63	[0.48-0.82]	0.001
Eye soreness	0.63	[0.54-0.73]	<0.0001	0.65	[0.54-0.79]	<0.0001	0.59	[0.45-0.76]	<0.0001
Diarrhoea	0.47	[0.40-0.55]	<0.0001	0.51	[0.41-0.63]	<0.0001	0.41	[0.32-0.53]	<0.0001
Shortness of breath	0.88	[0.74-1.03]	0.109	0.94	[0.76-1.15]	0.539	0.79	[0.60-1.03]	0.08
Low mood	0.6	[0.51-0.71]	<0.0001	0.65	[0.52-0.80]	<0.0001	0.56	[0.43-0.72]	<0.0001
Chest pain	0.79	[0.67-0.93]	0.005	0.78	[0.64-0.95]	0.014	0.83	[0.62-1.10]	0.191
Nausea	0.49	[0.41-0.58]	<0.0001	0.55	[0.44-0.69]	<0.0001	0.41	[0.31-0.54]	<0.0001
Tinnitus	0.73	[0.61-0.87]	0.001	0.74	[0.59-0.94]	0.011	0.71	[0.53-0.94]	0.016
Abdominal pain	0.6	[0.50-0.73]	<0.0001	0.59	[0.46-0.74]	<0.0001	0.64	[0.47-0.85]	0.002
Earache	0.85	[0.70-1.03]	0.089	0.91	[0.73-1.15]	0.43	0.72	[0.51-1.02]	0.064
Swollen glands	0.82	[0.68-0.99]	0.042	0.79	[0.63-1.00]	0.05	0.87	[0.62-1.23]	0.437
Sensation of skin burning	0.43	[0.35-0.53]	<0.0001	0.44	[0.34-0.57]	<0.0001	0.41	[0.29-0.59]	<0.0001
Delirium or reported confusion	0.6	[0.49-0.74]	<0.0001	0.56	[0.42-0.74]	<0.0001	0.69	[0.50-0.95]	0.024

Irregular heartbeat	0.6	[0.48-0.75]	<0.0001	0.66	[0.50-0.87]	0.003	0.5	[0.34-0.73]	<0.0001
OR = Odds ratio; CI = Confidence interval;									

Supplementary Figure 1. Histogram illustrating number of reported positive tests against number of days from first (blue bar) and second (orange bar) vaccine dose and for COVID-19 infection. NB these data are not adjusted for incidence of infection which changed over the same time period in the UK (29).



Supplementary Figure 2. Odds ratio of receiving the vaccine for all users who have recorded at least one COVID-19 test since 8th of December 2020. Univariate analysis for a) age, body mass index (BMI), comorbidity status and frailty; and b) Index of Multiple Deprivation category and healthy lifestyle factors, adjusted for age, BMI and sex and stratified by age group.

a)



b)



IMD = Index of Multiple Deprivation;;IMD[1-3] = high deprivation, IMD[8-10]= low deprivation; reference category for IMD is the intermediate category IMD [4-7]

Supplementary Figure 3. Comparison between the original univariate model, adjusted for age, body mass index and sex and the model adjusted for age, BMI, sex and mask-wearing



Supplementary Methods

Dietary Assessment

Diet was assessed using information obtained from an amended version of the Leeds Short Form Food Frequency Questionnaire that included 27 food items (50). Participants were asked how often on average they had consumed one portion of each food in a typical week during the month just prior (July 2020) to when they filled out the diet and lifestyle questionnaire. The responses had eight frequency categories ranging from “rarely or never” to “five or more times per day”. A healthy diet pattern was ascertained using the Diet Quality Score (DQS), a validated score for adherence to UK dietary guidelines (50). The DQS was computed from five broad categories including fruits, vegetables, total fat, oily fish, and non-milk extrinsic sugars. Each component was scored from 1 (unhealthiest) to 3 (healthiest) points, with intermediate values scored proportionally. All component scores were summed to obtain a total score ranging from 5 (lowest diet quality) to 15 (highest) points. We defined a healthier diet pattern as a DQS in the top quartile of the score distribution (score>=12points). To generate the lifestyle scores, the participants received 1 point for each healthy lifestyle factor. The sum of these four scores together gave a healthy lifestyle score ranging from 0 to 4, with higher scores indicating a healthier lifestyle.

References

1. Ledford H, Cyranoski D, Van Noorden R. The UK has approved a COVID vaccine - here's what scientists now want to know. Nature. 2020;588(7837):205-6.
2. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.
3. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.
4. Ramasamy MN, Minassian AM, Ewer KJ, Flaxman AL, Folegatti PM, Owens DR, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. The Lancet. 2020;396(10267):1979-93.
5. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
6. gov.uk. People who have received 1st dose vaccinations, by report date
UK total UK2021 [cited 2021 May 24th]. Available from: https://coronavirus.data.gov.uk/details/vaccinations.
7. Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases.
8. Lopez Bernal J, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088.
9. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet. 2021;397(10287):1819-29.
10. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, et al. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021;6(5):e335-e45.
11. SAGE 89 minutes: Coronavirus (COVID-19) response, 13 May 2021 2021 [cited 2021 May 24th]. Available from: https://www.gov.uk/government/publications/sage-89-minutes-coronavirus-covid-19-response-13-may-2021/sage-89-minutes-coronavirus-covid-19-response-13-may-2021.
12. Conor Egan SK, Kenneth Baillie, Ewen Harrison, Annemarie Docherty, Calum Semple Hospitalised vaccinated patients during the second wave, update April '21. UK; 2021 2021.
13. Annemarie B Docherty* RHM, Ewen M Harrison, Nazir Lone, Jonathan S NguyenVan-Tam, Peter JM Openshaw, J Kenneth Baillie, Malcolm G Semple…, for ISARIC4C investigators, . Changes in hospital mortality in the first wave of COVID-19 in the UK using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study.; 2021.
14. Nguyen LH, Drew DA, Graham MS, Joshi AD, Guo CG, Ma W, et al. Risk of COVID-19 among front-line health-care workers and the general community: a prospective cohort study. Lancet Public Health. 2020;5(9):e475-e83.
15. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. The Lancet Infectious Diseases. 2020;20(9):1034-42.
16. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5).
17. Hewitt J, Carter B, Vilches-Moraga A, Quinn TJ, Braude P, Verduri A, et al. The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study. The Lancet Public Health. 2020;5(8):e444-e51.
18. Petermann-Rocha F, Hanlon P, Gray SR, Welsh P, Gill JMR, Foster H, et al. Comparison of two different frailty measurements and risk of hospitalisation or death from COVID-19: findings from UK Biobank. BMC Med. 2020;18(1):355.
19. Sudre CH, Lee KA, Lochlainn MN, Varsavsky T, Murray B, Graham MS, et al. Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study app. Sci Adv. 2021;7(12).
20. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nature Medicine. 2021;27(4):626-31.

21. Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. Real-time tracking of self-reported symptoms to predict potential COVID-19. Nature Medicine. 2020;26(7):1037-40.
22. Spiel C, Lapka D, Gradinger P, Zodlhofer EM, Reimann R, Schober B, et al. A Euclidean distance-based matching procedure for nonrandomized comparison studies. European Psychologist. 2008;13(3):180-7.
23. Raîche M, Hébert R, Dubois MF. PRISMA-7: a case-finding tool to identify older adults with moderate to severe disabilities. Arch Gerontol Geriatr. 2008;47(1):9-18.
24. Zazzara MB, Penfold RS, Roberts AL, Lee KA, Dooley H, Sudre CH, et al. Probable delirium is a presenting symptom of COVID-19 in frail, older adults: a cohort study of 322 hospitalised and 535 community-based older adults. Age Ageing. 2021;50(1):40-8.
25. Hoffmann S, Wiben A, Kruse M, Jacobsen KK, Lembeck MA, Holm EA. Predictive validity of PRISMA-7 as a screening instrument for frailty in a hospital setting. BMJ Open. 2020;10(10):e038768.
26. Ministry of Housing & Communities & Local Government. English indices of deprivation 2015. (2015).
27. Chiuve SE, Cook NR, Shay CM, Rexrode KM, Albert CM, Manson JE, et al. Lifestyle-based prediction model for the prevention of CVD: the Healthy Heart Score. J Am Heart Assoc. 2014;3(6):e000954.
28. Murray B, Kerfoot E, Graham M, Sudre C, Molteni E, Canas L, et al. Accessible Data Curation and Analytics for International-Scale Citizen Science Datasets2020.
29. Mansournia MA, Altman DG. Inverse probability weighting. Bmj. 2016;352:i189.
30. GOV.UK. Coronavirus (COVID-19) in the UK: GOV.UK 2021 [cited 2021 May 24th]. Available from: https://coronavirus.data.gov.uk/.
31. Shrotri M, Fragaszy E, Geismar C, Nguyen V, Beale S, Braithwaite I, et al. Spike-antibody responses following first and second doses of ChAdOx1 and BNT162b2 vaccines by age, gender, and clinical factors - a prospective community cohort study (Virus Watch). medRxiv. 2021:2021.05.12.21257102.
32. David Bell (University of Stirling) AC-HCPaEC, London School of, Economics and Political Science) DHENU, Scottish Centre for, Administrative Data Research) SJLWaLEELUo, Edinburgh EHE, Mirko Moro (University of Stirling), Siobhán Murphy (Centre for Public, Health QUB, Dermot O'Reilly (Centre for Public Health, Queens University Belfast), Pietro, Economics) PLWaL. COVID-19 mortality and long-term care: a UK comparison. UK; 2020 Last updated August 2020.
33. Hazeldine J, Lord JM. Innate immunesenescence: underlying mechanisms and clinical relevance. Biogerontology. 2015;16(2):187-201.
34. Oh SJ, Lee JK, Shin OS. Aging and the Immune System: the Impact of Immunosenescence on Viral Infection, Immunity and Vaccine Immunogenicity. Immune Netw. 2019;19(6):e37.
35. Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nature Communications. 2021;12(1):905.
36. The Health Protection (Coronavirus, Restrictions) (England) Regulations 2020, Regulations made by the Secretary of State, laid before Parliament under section 45R of the Public Health (Control of Disease) Act 1984 (c. 22) (2020).
37. Glenn DA, Hegde A, Kotzen E, Walter EB, Kshirsagar AV, Falk R, et al. Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease. Kidney Int Rep. 2021;6(5):1407-10.
38. Krueger KM, Ison MG, Ghossein C. Practical Guide to Vaccination in All Stages of CKD, Including Patients Treated by Dialysis or Kidney Transplantation. Am J Kidney Dis. 2020;75(3):417-25.
39. Syed-Ahmed M, Narayanan M. Immune Dysfunction and Risk of Infection in Chronic Kidney Disease. Adv Chronic Kidney Dis. 2019;26(1):8-15.
40. Shroff RT, Chalasani P, Wei R, Pennington D, Quirk G, Schoenle MV, et al. Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy. medRxiv. 2021:2021.05.13.21257129.
41. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020;323(20):2052-9.
42. Bowyer RCE, Varsavsky T, Thompson EJ, Sudre CH, Murray BAK, Freidin MB, et al. Geo-social gradients in predicted COVID-19 prevalence in Great Britain: results from 1 960 242 users of the COVID-19 Symptoms Study app. Thorax. 2020.
43. Bray I, Gibson A, White J. Coronavirus disease 2019 mortality: a multivariate ecological analysis in relation to ethnicity, population density, obesity, deprivation and pollution. Public Health. 2020;185:261-3.
44. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430-6.

45. Office for National Statistics. Coronavirus and vaccine hesitancy, Great Britain: 13 January to 7 February 2021. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandwellbeing/bulletins/coronavirusandvaccinehesitancygreatbritain/13januaryto7february2021. Accessed May 24, 2021.
46. Songu M, Cingi C. Sneeze reflex: facts and fiction. Therapeutic Advances in Respiratory Disease. 2009;3(3):131-41.
47. Varsavsky T, Graham MS, Canas LS, Ganesh S, Capdevila Pujol J, Sudre CH, et al. Detecting COVID-19 infection hotspots in England using large-scale self-reported data from a mobile application: a prospective, observational study. The Lancet Public Health. 2021;6(1):e21-e9.
48. Joint Committee on Vaccination and Immunisation: advice on priority groups for COVID-19 vaccination 30 December 2020
49. O'Caoimh R, Costello M, Small C, Spooner L, Flannery A, O'Reilly L, et al. Comparison of Frailty Screening Instruments in the Emergency Department. Int J Environ Res Public Health. 2019;16(19).
50. Cleghorn, C.L., et al., Can a dietary quality score derived from a short-form FFQ assess dietary quality in UK adult population surveys? Public Health Nutr, 2016. 19(16): p. 2915-2923.